Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Healios KK ( (JP:4593) ) has provided an update.
Healios KK announced the publication of clinical data from the ONE-BRIDGE trial in a leading Japanese journal, enhancing the credibility of their application for conditional approval of HLCM051 for ARDS treatment. The study showed promising results, including an extension of ventilator-free days and reduced mortality, supporting the therapeutic potential of their product.
More about Healios KK
Healios KK is a company operating in the regenerative medicine industry, focusing on developing cell therapies for conditions like Acute Respiratory Distress Syndrome (ARDS).
YTD Price Performance: 57.06%
Average Trading Volume: 3,479,307
Technical Sentiment Consensus Rating: Sell
Current Market Cap: Yen27.34B
For detailed information about 4593 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue